Newsfiscal.ai
Moleculin Biotech Completes Dosing in Part A of Pivotal MIRACLE Trial
· Published
Article summary
Moleculin Biotech, Inc. has finished dosing patients for Part A of its Phase 2/3 MIRACLE clinical trial, which evaluates the combination of Annamycin and cytarabine for relapsed or refractory acute myeloid leukemia.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…